Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Maintenance Poly (ADP-ribose) Polymerase Inhibitor Therapy for Ovarian Cancer: Precision Oncology or One Size Fits All?

Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 20 Dec 2017

Berchuck Andrew, Secord Angeles Alvarez, Moss Haley A, Havrilesky Laura J

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Clinical Decision-Making
Share to Cost-Benefit Analysis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Costs

Share to Maintenance Chemotherapy

Share to Ovarian Neoplasms

Share to Poly(ADP-ribose) Polymerase Inhibitors

Share to Precision Medicine

Source

Identifiers

PMID: 29072978
DOI: 10.1200/JCO.2017.74.5752

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Maintenance Poly (ADP-ribose) Polymerase Inhibitor Therapy for Ovarian Cancer: Precision Oncology or One Size Fits All?PMID 29072978Read ↗

Poly (ADP-ribose) polymerase inhibitors in the management of ovarian cancer.Semantic proximity Read ↗

Current Ovarian Cancer Maintenance Strategies and Promising New DevelopmentsSemantic proximity Read ↗

First-line PARP inhibition in ovarian cancer - standard of care for all?Semantic proximity Read ↗

A Pan-Canadian Consensus Statement on First-Line PARP Inhibitor Maintenance for Advanced, High-Grade Serous and Endometrioid Tubal, Ovarian, and Primary Peritoneal Cancers.Semantic proximity Read ↗

Using PARP Inhibitors in Frontline Maintenance Therapy for Ovarian Cancer.Semantic proximity Read ↗

Stereotactic Body Radiation Therapy for Oligoprogressive Ovarian Cancer Patients Treated During Poly(ADP-Ribose)-Polymerase Inhibitor Maintenance: Efficacy and Adverse Events From the Epimetheo Retrospective StudySemantic proximity Read ↗

Poly(ADP-Ribose) Polymerase InhibitorsSemantic proximity Read ↗

Overall Survival and the Evolving Benefit-Risk Assessment for Poly (ADP-ribose) Polymerase Inhibitors in Advanced Ovarian CancerSemantic proximity Read ↗

PARP Inhibitors in the Management of Ovarian Cancer: ASCO GuidelineSemantic proximity Read ↗

Identification of DNA Repair Pathways That Affect the Survival of Ovarian Cancer Cells Treated with a Poly(ADP-Ribose) Polymerase Inhibitor in a Novel Drug CombinationSemantic proximity Read ↗

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trialSemantic proximity Read ↗

Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.